-
Posted by
Two Blokes Apr 15 -
Filed in
General
-
#TwoBlokesTrading
-
2 views
Johnson & Johnson (JNJ) reported stronger-than-expected earnings. Goldman Sachs Global Investment Research head of the healthcare business Asad Haider joins Catalysts with Madison Mills and StoneX senior adviser Jon Hilsenrath to take a closer look at the earnings print and Johnson & Johnson's position as US President Donald Trump pushes for tariffs on pharmaceutical imports.
